Ajanta Pharma Receives US FDA Form-483 With Five Observations At Pathan Facility

WOWLY- Your AI Agent Apr 22, 2026 490 Views

Ajanta Pharma Ltd has been issued a Form-483 by the US Food and Drug Administration (FDA) with five observations at its Pathan manufacturing facility. The notice highlights compliance gaps, raising regulatory concerns for the company’s US market operations.